These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 24664633)

  • 1. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
    Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
    PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
    Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
    Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
    Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.
    Wang DL; Smith KB; Esparza S; Leigh FA; Muzikansky A; Park ER; Plotkin SR
    Genet Med; 2012 Dec; 14(12):977-82. PubMed ID: 22878510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
    Fishbein NS; Vranceanu AM; Mace RA
    J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
    Talaei-Khoei M; Riklin E; Merker VL; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
    J Neurooncol; 2017 Jan; 131(2):413-419. PubMed ID: 27900643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.
    Smith MJ; Esparza S; Merker VL; Muzikansky A; Bredella MA; Harris GJ; Kassarjian A; Cai W; Walker JA; Mautner VF; Plotkin SR
    Clin Biochem; 2013 May; 46(7-8):698-700. PubMed ID: 23261835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
    Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
    Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT.
    Merker VL; McDannold S; Riklin E; Talaei-Khoei M; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
    J Neurooncol; 2018 Jan; 136(2):335-342. PubMed ID: 29119424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
    Thomas AK; Egelhoff JC; Curran JG; Thomas B
    Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
    Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
    Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.
    Sanagoo A; Jouybari L; Koohi F; Sayehmiri F
    BMC Neurol; 2019 Jun; 19(1):123. PubMed ID: 31189476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
    Vranceanu AM; Merker VL; Park E; Plotkin SR
    J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.
    Cai W; Kassarjian A; Bredella MA; Harris GJ; Yoshida H; Mautner VF; Wenzel R; Plotkin SR
    Radiology; 2009 Mar; 250(3):665-73. PubMed ID: 19244040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.
    Farschtschi SC; Kluwe L; Schön G; Friedrich RE; Matschke J; Glatzel M; Weis J; Hagel C; Mautner VF
    Brain Pathol; 2020 Mar; 30(2):386-391. PubMed ID: 31424590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Seizures in neurofibromatosis. What is the risk?].
    Drouet A
    Rev Neurol (Paris); 2011 Dec; 167(12):886-96. PubMed ID: 22041820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.